VRCA logo

Verrica Pharmaceuticals Inc.

VRCA
Healthcare|Biotechnology|US
$3.19
+0.10 (+3.24%)
Tangible Book / Share
$0.20
Cash / Share
$0.53
Next Earnings Report
Nov 12, 2026
EPS est. -$0.50 · Revenue est. $6.2M
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Dec 23, 2025 (424B3). Possible dilution.

Upcoming Data Readouts (2)

May 2027
Est. completion
P3Common Warts
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
NCT07637734n=300
Nov 2027
Est. completion
P3Common Warts (Verruca Vulgaris)
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
NCT07457918n=250

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2026
P3
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
NCT07246590

Recent Press Releases

Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
Nov 5, 2026 · GlobeNewsWire
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
Oct 22, 2026 · GlobeNewsWire
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
Sep 30, 2026 · GlobeNewsWire
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
Sep 10, 2026 · GlobeNewsWire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026 · GlobeNewsWire
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
Aug 27, 2026 · GlobeNewsWire

SEC Filings (64)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jun 9, 20268-KMaterial eventDocumentIndex
May 12, 2026S-8Employee stock planDocumentIndex
May 12, 202610-QQuarterly reportDocumentIndex
May 12, 20268-KMaterial eventDocumentIndex
Apr 20, 2026ARSAnnual report to holdersDocumentIndex
Apr 20, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 20, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 11, 202610-KAnnual reportDocumentIndex
Mar 11, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 29, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Dec 30, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Dec 30, 20258-KMaterial eventDocumentIndex
Dec 23, 2025EFFECTDocumentIndex
Dec 23, 2025424B3Offering prospectusDocumentIndex
Dec 15, 2025S-3Shelf registrationDocumentIndex
Dec 10, 2025DDocumentIndex
Dec 3, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 28, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Nov 24, 2025SC 13DActivist / 5%+ stakeDocumentIndex
Nov 24, 20258-KMaterial eventDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 202510-QQuarterly reportDocumentIndex
Nov 14, 20258-KMaterial eventDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 12, 202510-QQuarterly reportDocumentIndex
Aug 12, 20258-KMaterial eventDocumentIndex
Jul 30, 20258-KMaterial eventDocumentIndex
Jul 23, 20258-KMaterial eventDocumentIndex
Jul 1, 20258-KMaterial eventDocumentIndex
Jun 12, 20258-KMaterial eventDocumentIndex
Jun 5, 20258-KMaterial eventDocumentIndex
May 15, 2025SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2025SC 13G/APassive 5%+ stakeDocumentIndex
May 13, 2025S-8Employee stock planDocumentIndex
May 13, 202510-QQuarterly reportDocumentIndex
May 13, 20258-KMaterial eventDocumentIndex
Apr 30, 2025DEFR14ADocumentIndex